Hefei Huafang Medicine Technology Co., Ltd.

Main objective: Using pharmacokinetic parameters as the primary endpoint evaluation indicators, the pharmacokinetic behavior of the test preparation sildenafil citrate orodispersible film (licensed by: Hefei Huafang Pharmaceutical Technology Co., Ltd.) and the reference preparation sildenafil citrate orodispersible film (licensed by: Viatris Pharmaceutical Co., Ltd., trade name: Viagra®) in healthy subjects after oral administration in the fasting/postprandial state was compared, and the bioequivalence of the two preparations was evaluated. Secondary objectives: To observe the safety of the test sildenafil citrate oral dissolving film and the reference sildenafil citrate oral dissolving film in healthy subjects; to evaluate the palatability (overall taste, peculiar smell, sweetness, aroma, bitterness evaluation), grittiness, dissolution time, mucosal adhesion and irritation of the test sildenafil citrate oral dissolving film and the reference sildenafil citrate oral dissolving film.

The main purpose of the study is to use the doxazosin mesylate sustained-release tablets owned by Hefei Huafang Pharmaceutical Technology Co., Ltd. as the test preparation and the doxazosin mesylate sustained-release tablets (trade name: Kadova®) owned by Pfizer Pharma PFE GmbH as the reference preparation. According to the relevant provisions of the bioequivalence test, the pharmacokinetic behavior of the two preparations in healthy Chinese subjects is compared to evaluate the bioequivalence of the two preparations. Secondary purpose of the study: To evaluate the safety of the test preparation and the reference preparation after a single oral administration on an empty stomach in healthy Chinese subjects.

The main purpose of the study is to use the doxazosin mesylate sustained-release tablets owned by Hefei Huafang Pharmaceutical Technology Co., Ltd. as the test preparation and the doxazosin mesylate sustained-release tablets (trade name: Kadova®) owned by Pfizer Pharma PFE GmbH as the reference preparation. According to the relevant provisions of the bioequivalence test, the pharmacokinetic behavior of the two preparations in healthy Chinese subjects is compared to evaluate the bioequivalence of the two preparations. Secondary purpose of the study: To evaluate the safety of the test preparation and the reference preparation after a single oral administration to healthy Chinese subjects after a meal.